ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B Turnover 34.18%
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+22.32%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
+$487M
Cap. Flow
+$166M
Cap. Flow %
7.61%
Top 10 Hldgs %
40.83%
Holding
354
New
43
Increased
102
Reduced
64
Closed
78
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.9 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ABVX icon
Abivax
ABVX
+$46.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$38.5M
3
ZLAB icon
Zai Lab
ZLAB
+$38.4M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$34.8M
5
EDIT icon
Editas Medicine
EDIT
+$26M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$48.2M
2
BEAM icon
Beam Therapeutics
BEAM
+$34.5M
3
SRRK icon
Scholar Rock
SRRK
+$20M
4
DNLI icon
Denali Therapeutics
DNLI
+$17.3M
5
CYTK icon
Cytokinetics
CYTK
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 86.67%
2 Miscellaneous 11.02%
3 Financials 2.15%
4 Real Estate 0.05%
5 Communication Services 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ZURA icon
51
Zura Bio
ZURA
$423M
$10.4M 0.48%
1,759,295
+1,128,892
+179% +$5.38M
2024 Q3
7 quarters
OKUR icon
52
OnKure Therapeutics
OKUR
$91.1M
$10.2M 0.47%
2,238,684
-196,257
-8% -$842K
2025 Q4
2 quarters
MAZE icon
53
Maze Therapeutics
MAZE
$1.46B
$10.1M 0.46%
339,276
+289,181
+577% +$7.58M
2025 Q3
3 quarters
XENE icon
54
Xenon Pharmaceuticals
XENE
$3.28B
$10.1M 0.46%
166,550
-62,349
-27% -$3.46M
2024 Q2
8 quarters
TEVA icon
55
Teva Pharmaceutical Industries Limited
TEVA
$47.5B
$9.41M 0.43%
277,848
+9,457
+4% +$315K
2023 Q4
10 quarters
URGN icon
56
UroGen Pharma
URGN
$1.79B
$9.29M 0.43%
252,395
-143,064
-36% -$3.88M
2025 Q2
4 quarters
FTH icon
57
Faeth Therapeutics
FTH
$517M
$9.03M 0.41%
+361,010
New +$8.35M
2026 Q2
0 quarters
AMLX icon
58
Amylyx Pharmaceuticals
AMLX
$3.39B
$8.88M 0.41%
494,378
-506,226
-51% -$7.83M
2025 Q1
5 quarters
DBVT icon
59
DBV Technologies S.A. American Depositary Shares
DBVT
$557M
$8.66M 0.4%
528,295
-484,571
-48% -$9.14M
2026 Q1
1 quarter
SVRA icon
60
Savara
SVRA
$978M
$8.64M 0.4%
1,403,409
-61,126
-4% -$328K
2024 Q1
9 quarters
PCVX icon
61
Vaxcyte
PCVX
$10.6B
$8.49M 0.39%
146,034
-113,103
-44% -$6.14M
2025 Q1
5 quarters
CGON icon
62
CG Oncology
CGON
$5.48B
$8.43M 0.39%
118,664
-67,035
-36% -$4.38M
2024 Q1
9 quarters
MLYS icon
63
Mineralys Therapeutics
MLYS
$1.84B
$8.06M 0.37%
298,886
+144,200
+93% +$3.96M
2024 Q1
9 quarters
ASND icon
64
Ascendis Pharma A/S
ASND
$14.9B
$7.63M 0.35%
28,604
+3,590
+14% +$839K
2023 Q4
10 quarters
AMAN icon
65
Amanat Acquisition Corp
AMAN
$100M
$7.62M 0.35%
+750,000
New +$7.57M
2026 Q2
0 quarters
NRIX icon
66
Nurix Therapeutics
NRIX
$2.59B
$7.6M 0.35%
313,236
+257,166
+459% +$4.38M
2024 Q4
6 quarters
BHVN icon
67
Biohaven
BHVN
$1.65B
$7.47M 0.34%
501,687
+456,910
+1,020% +$4.92M
2025 Q1
5 quarters
PRME icon
68
Prime Medicine
PRME
$568M
$7.37M 0.34%
1,997,552
+24,270
+1% +$80.6K
2026 Q1
1 quarter
PCSC
69
DELISTED
Perceptive Capital Solutions
PCSC
$7.34M 0.34%
674,695
+175,114
+35% +$1.95M
2024 Q2
8 quarters
IRD icon
70
Opus Genetics
IRD
$341M
$7.33M 0.34%
1,783,781
-65,223
-4% -$304K
2025 Q4
2 quarters
LXEO icon
71
Lexeo Therapeutics
LXEO
$216M
$7.29M 0.33%
1,565,950
+98,600
+7% +$533K
2024 Q2
8 quarters
DMRA
72
Damora Therapeutics
DMRA
$1.14B
$7.28M 0.33%
280,000
+1,000
+0.4% +$24.2K
2026 Q1
1 quarter
REPL icon
73
Replimune Group
REPL
$1.07B
$7.26M 0.33%
655,784
-927,203
-59% -$5.67M
2025 Q2
4 quarters
LONA icon
74
LeonaBio Inc
LONA
$50.8M
$7.14M 0.33%
777,100
+49,619
+7% +$462K
2025 Q4
2 quarters
KRRO icon
75
Korro Bio
KRRO
$131M
$7.12M 0.33%
540,054
– –
2026 Q1
1 quarter
1 2
3
4 5

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, ADAR1 Capital Management held 354 positions worth $2.19B, up 29% from $1.7B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

ADAR1 Capital Management deployed $166M of net new capital in Q2 2026, opening 43 new positions and adding to 102 existing holdings. Its largest new stake was Editas Medicine: 8,889,000 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Denali Therapeutics, an estimated $17.3M trimmed.

  • ADAR1 Capital Management's largest Q2 2026 buy was Editas Medicine: 8,889,000 shares worth $28.8M.
  • ADAR1 Capital Management added most to Abivax in Q2 2026, an estimated $46.5M increase.
  • ADAR1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $17.3M.
  • ADAR1 Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $48.2M.
  • ADAR1 Capital Management's ten largest holdings make up 41% of its $2.19B portfolio in Q2 2026.
  • ADAR1 Capital Management opened 43 new positions and closed 78 in Q2 2026.
  • ADAR1 Capital Management's portfolio value rose 29% quarter-over-quarter to $2.19B.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.